Recent advances in antibody‐based therapies for Hodgkin Lymphoma

Although a poster child for the development and refinement of multi‐modal multi‐agent therapeutic strategies, Hodgkin Lymphoma has, until recently, lagged behind other lymphomas in terms of the use of therapeutic monoclonal antibodies. This situation has now changed dramatically, with the rapid emergence both of a toxin‐conjugated tumour‐selective anti‐CD30 antibody, and of antibodies targeting immunological checkpoints, most notably PD‐1 (also termed PDCD1). The former provides an efficient targeting vehicle for delivery of a potent synthetic anti‐mitotic drug, with ultimate efficacy independent of immunological activity. The latter are members of a class of drugs representing a new paradigm in immune‐oncological therapies that are designed to enhance pre‐existent anti‐tumour T cell activities. The role of both in the overall treatment pathway will continue to evolve over coming years. Hodgkin Lymphoma has once again become emblematic of the major trend shifts in cancer therapy.